Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer
Olema Pharmaceuticals, Inc. (OLMA)
Company Research
Source: GlobeNewswire
SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced the advancement of OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), into Phase 2 clinical development for the treatment of ER+/HER2- metastatic breast cancer. “We are excited about the potential of OP-1250 and are expeditiously advancing the development program as we work to further position OP-1250 as a differentiated CERAN and potential endocrine therapy of choice for ER+ breast cancer.” said Naseem Zojwalla, M.D., Chief Medical Officer of Olema Oncology. “Enrollment is underway in Phase 2 monotherapy, and we look forward to further evaluating OP-1250’s benefit in treating ER+/HER2- breast cancer patients.” Selection of the recommended Phase 2 dose (RP2D) of 120 mg OP-1250 once-daily was based on pharmacokinetics, safety and tolerability, and encouraging early anti-tumor activity from Phase 1b e
Show less
Read more
Impact Snapshot
Event Time:
OLMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OLMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OLMA alerts
High impacting Olema Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
OLMA
News
- FATE, ALPN and RLAY are among after hour movers [Seeking Alpha]Seeking Alpha
- Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual ConferenceGlobeNewswire
- Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]Yahoo! Finance
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $24.00 price target on the stock.MarketBeat
OLMA
Earnings
- 3/11/24 - In-Line
OLMA
Sec Filings
- 3/29/24 - Form 4
- 3/28/24 - Form 144
- 3/22/24 - Form SC
- OLMA's page on the SEC website